Kiniksa Pharmaceuticals LtdNASDAQ:KNSA
- LAST PRICE19.1700
- TODAY'S CHANGE (%)-0.1000 (-0.5189%)
- Bid / Lots19.0000/ 3
- Ask / Lots19.6500/ 2
- Open / Previous Close19.2300 / 19.2700
- Day Range
- 52 Week Range
- Volume279,094
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KNSA |
|---|---|---|
| 09:32 ET | 5071 | 19.255 |
| 09:34 ET | 100 | 19.14 |
| 09:36 ET | 540 | 19.05 |
| 09:38 ET | 200 | 19.105 |
| 09:39 ET | 5000 | 19.1193 |
| 09:41 ET | 400 | 19.12 |
| 09:45 ET | 680 | 19.12 |
| 09:48 ET | 100 | 19.1 |
| 09:50 ET | 617 | 19.07 |
| 09:52 ET | 756 | 19.02 |
| 09:56 ET | 300 | 19.04 |
| 09:57 ET | 600 | 19.11 |
| 10:03 ET | 100 | 19.105 |
| 10:08 ET | 200 | 19.135 |
| 10:10 ET | 200 | 19.135 |
| 10:12 ET | 931 | 19.19 |
| 10:14 ET | 100 | 19.205 |
| 10:15 ET | 200 | 19.25 |
| 10:19 ET | 200 | 19.24 |
| 10:21 ET | 867 | 19.26 |
| 10:24 ET | 400 | 19.25 |
| 10:30 ET | 100 | 19.25 |
| 10:35 ET | 114 | 19.23 |
| 10:42 ET | 500 | 19.275 |
| 10:44 ET | 1300 | 19.24 |
| 10:51 ET | 968 | 19.24 |
| 10:55 ET | 203 | 19.2453 |
| 10:57 ET | 300 | 19.24 |
| 11:00 ET | 100 | 19.24 |
| 11:02 ET | 300 | 19.26 |
| 11:06 ET | 200 | 19.305 |
| 11:08 ET | 300 | 19.31 |
| 11:09 ET | 500 | 19.35 |
| 11:11 ET | 200 | 19.37 |
| 11:15 ET | 300 | 19.36 |
| 11:18 ET | 100 | 19.37 |
| 11:24 ET | 500 | 19.38 |
| 11:26 ET | 100 | 19.385 |
| 11:27 ET | 1250 | 19.3404 |
| 11:31 ET | 620 | 19.4 |
| 11:36 ET | 835 | 19.39 |
| 11:38 ET | 100 | 19.375 |
| 11:40 ET | 110 | 19.37 |
| 11:42 ET | 200 | 19.39 |
| 11:45 ET | 200 | 19.38 |
| 11:49 ET | 300 | 19.405 |
| 11:51 ET | 100 | 19.4 |
| 11:54 ET | 100 | 19.415 |
| 11:58 ET | 300 | 19.42 |
| 12:02 ET | 1903 | 19.43 |
| 12:05 ET | 100 | 19.425 |
| 12:09 ET | 100 | 19.41 |
| 12:12 ET | 300 | 19.41 |
| 12:14 ET | 600 | 19.38 |
| 12:16 ET | 200 | 19.375 |
| 12:21 ET | 500 | 19.37 |
| 12:25 ET | 100 | 19.39 |
| 12:34 ET | 400 | 19.39 |
| 12:36 ET | 200 | 19.37 |
| 12:38 ET | 300 | 19.37 |
| 12:41 ET | 500 | 19.34 |
| 12:43 ET | 200 | 19.3275 |
| 12:45 ET | 400 | 19.32 |
| 12:48 ET | 517 | 19.27 |
| 12:50 ET | 100 | 19.24 |
| 12:56 ET | 300 | 19.25 |
| 12:57 ET | 600 | 19.21 |
| 12:59 ET | 100 | 19.205 |
| 01:01 ET | 200 | 19.22 |
| 01:03 ET | 100 | 19.22 |
| 01:06 ET | 100 | 19.2 |
| 01:10 ET | 100 | 19.185 |
| 01:14 ET | 400 | 19.185 |
| 01:15 ET | 200 | 19.19 |
| 01:19 ET | 600 | 19.17 |
| 01:21 ET | 718 | 19.18 |
| 01:24 ET | 100 | 19.17 |
| 01:26 ET | 200 | 19.17 |
| 01:28 ET | 684 | 19.21 |
| 01:32 ET | 200 | 19.23 |
| 01:33 ET | 300 | 19.22 |
| 01:35 ET | 222 | 19.18 |
| 01:39 ET | 240 | 19.15 |
| 01:44 ET | 6900 | 19.2 |
| 01:48 ET | 100 | 19.19 |
| 01:51 ET | 100 | 19.23 |
| 01:53 ET | 200 | 19.19 |
| 01:55 ET | 100 | 19.195 |
| 01:57 ET | 200 | 19.18 |
| 02:00 ET | 8784 | 19.15 |
| 02:02 ET | 200 | 19.12 |
| 02:04 ET | 400 | 19.1 |
| 02:08 ET | 100 | 19.12 |
| 02:09 ET | 1401 | 19.14 |
| 02:11 ET | 100 | 19.15 |
| 02:13 ET | 100 | 19.13 |
| 02:18 ET | 100 | 19.14 |
| 02:20 ET | 600 | 19.13 |
| 02:22 ET | 300 | 19.13 |
| 02:24 ET | 800 | 19.1 |
| 02:26 ET | 5234 | 19.03 |
| 02:27 ET | 427 | 19.1 |
| 02:31 ET | 400 | 19.1 |
| 02:33 ET | 100 | 19.08 |
| 02:36 ET | 100 | 19.09 |
| 02:38 ET | 1263 | 19.105 |
| 02:42 ET | 400 | 19.075 |
| 02:44 ET | 200 | 19.07 |
| 02:49 ET | 100 | 19.05 |
| 02:51 ET | 300 | 19.06 |
| 02:54 ET | 700 | 19.06 |
| 02:58 ET | 100 | 19.06 |
| 03:00 ET | 200 | 19.06 |
| 03:02 ET | 250 | 19.08 |
| 03:03 ET | 917 | 19.13 |
| 03:05 ET | 100 | 19.13 |
| 03:07 ET | 900 | 19.095 |
| 03:09 ET | 800 | 19.09 |
| 03:12 ET | 500 | 19.11 |
| 03:14 ET | 201 | 19.105 |
| 03:16 ET | 459 | 19.1141 |
| 03:18 ET | 100 | 19.13 |
| 03:20 ET | 841 | 19.11 |
| 03:21 ET | 100 | 19.13 |
| 03:23 ET | 955 | 19.15 |
| 03:27 ET | 720 | 19.12 |
| 03:30 ET | 100 | 19.12 |
| 03:34 ET | 1368 | 19.15 |
| 03:39 ET | 1500 | 19.18 |
| 03:41 ET | 1108 | 19.16 |
| 03:43 ET | 200 | 19.16 |
| 03:45 ET | 200 | 19.17 |
| 03:48 ET | 928 | 19.16 |
| 03:50 ET | 100 | 19.17 |
| 03:52 ET | 1200 | 19.2 |
| 03:54 ET | 550 | 19.17 |
| 03:56 ET | 3425 | 19.14 |
| 03:57 ET | 2329 | 19.16 |
| 03:59 ET | 4697 | 19.17 |
May 7, 2024
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference, from 4:01PM ET on Tuesday May 07, 2024 by Dow Jones
4:01PM ET on Tuesday May 07, 2024 by Dow Jones
May 3, 2024
DJ Kiniksa Pharmaceuticals Initiated at Overweight by Wells Fargo, from 11:59AM ET on Friday May 03, 2024 by Dow Jones
11:59AM ET on Friday May 03, 2024 by Dow Jones
May 1, 2024
DJ Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan, from 10:58AM ET on Wednesday May 01, 2024 by Dow Jones
10:58AM ET on Wednesday May 01, 2024 by Dow Jones
Apr 24, 2024
DJ Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group, from 1:50PM ET on Wednesday Apr 24, 2024 by Dow Jones
1:50PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 23, 2024
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution, from 7:30AM ET on Tuesday Apr 23, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.4B | 225.0x | --- |
Ginkgo Bioworks Holdings Inc | 1.6B | -1.5x | --- |
BioCryst Pharmaceuticals Inc | 1.4B | -5.9x | --- |
Dynavax Technologies Corp | 1.6B | 237.2x | --- |
MannKind Corp | 1.3B | 205.7x | --- |
MiMedx Group Inc | 1.2B | 20.6x | --- |
Company Information
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Contact Information
- Headquarters
- Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Sanjiv Patel
- Chief Financial Officer, Senior Vice President
- Mark Ragosa
- Chief Operating Officer, Senior Vice President
- Eben Tessari
- Senior Vice President and Chief Commercial Officer
- Ross Moat
- Senior Vice President and Chief Medical Officer
- John Paolini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
|---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.33 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 225.0x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | 125.9x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
